Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Oramed Pharmaceuticals buy melinda

Oramed Pharmaceuticals
Start price
€3.30
29.03.19 / 50%
Target price
€5.86
30.10.19
Performance (%)
-10.34%
End price
€2.96
30.10.19
Summary
This prediction ended on 30.10.19 with a price of €2.96. The prediction for Oramed Pharmaceuticals disappointed with a performance of -10.34%. melinda has 50% into this prediction

Oramed is a pharmaceutical company that focuses on the development of innovative oral delivery solutions for drugs that are traditionally administered through injection. The company is primarily dedicated to the development of an oral insulin capsule that can potentially revolutionize the treatment of diabetes. Their flagship product, ORMD-0801, is currently in Phase III clinical trials in the United States and has received Fast Track designation from the FDA. Oramed is a publicly traded company listed on the Nasdaq under the ticker symbol ORMP.

Performance without dividends (%)
Name 1w 1m 1y 3y
Oramed Pharmaceuticals 1.039% 1.039% 5.630% -74.746%
iShares Core DAX® 2.594% -1.158% 14.782% 16.813%
iShares Nasdaq 100 3.553% -1.727% 43.265% 44.227%
iShares Nikkei 225® 0.687% -8.354% 18.454% 1.361%
iShares S&P 500 2.209% -0.942% 31.361% 42.812%

According to melinda what are the pros and cons of Oramed Pharmaceuticals for the foreseeable future?

Pros
Could be worthwhile Investment >10% per year
Cons

Comments by melinda for this prediction

In the thread Oramed Pharmaceuticals diskutieren
Prediction Buy
Perf. (%) -10.34%
Target price 5.863
Change
Ends at 30.10.19

Secteur Recherche biotechnologique et médicale

Oramed Pharmaceuticals Inc. (Oramed) est active dans le domaine des solutions d'administration orale de médicaments et de vaccins actuellement administrés par injection. Le produit phare d'Oramed, une capsule d'insuline ingérable par voie orale en phase II des essais cliniques, est axé sur le traitement du diabète. La Société met au point une technologie d'administration orale de protéines ingérables par voie orale (POD) pour l'administration de médicaments actuellement administrés par injection. La plateforme d'administration d'Oramed protège les sables protéiques et améliore leur absorption, leur permettant d'atteindre le flux sanguin par la veine porte. Les produits de la Société comprennent ORMD-0801, capsule d'insuline orale ; ORMD 0901, capsule d'exenatide orale ; et traitement combiné ORMD 0801 + ORMD 0901. ORMD-0801 est en phase II A d'essais cliniques. ORMD-0901 est à l'étape préclinique ou de recherche sur un nouveau médicament (DNR) en phase I B.


Nombre d'employés

: 13 personnes.

melinda 
0
Report Share
29.03.19
Prediction Buy
Perf. (%) -10.34%
Target price 5.863
Change
Ends at 30.10.19

Buy closed

melinda 
0
Report Share
30.10.19

Stopped prediction by melinda for Oramed Pharmaceuticals

buy
Oramed Pharmaceuticals

Start price
Target price
Perf. (%)
€11.38
29.12.21
€15.00
29.12.22
-0.92%
30.12.22

Could be worthwhile Investment >10% per year
melinda 
29.12.21 50%
buy
Oramed Pharmaceuticals

Start price
Target price
Perf. (%)
€2.96
30.10.19
-
04.11.21
698.99%
05.11.21

Could be worthwhile Investment >10% per year
melinda 
30.10.19 50%
buy
Oramed Pharmaceuticals

Start price
Target price
Perf. (%)
€6.53
01.03.18
€8.30
03.09.18
-31.63%
03.09.18

Could be worthwhile Investment >10% per year
melinda 
18.08.19 50%